Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

(2012) Ashutosh Lal et al.   BLOOD CELLS MOLECULES AND DISEASES

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

(2011) Y. Aydinok et al.   HAEMATOLOGICA

Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers

(2011) N.P. Morales et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia

(2010) Lie Michael George Limenta et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics, Metabolism, and Disposition of Deferasirox in  -Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State

(2010) F. Waldmeier et al.   DRUG METABOLISM AND DISPOSITION

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone

(2010) Patricia Evans et al.   Translational Research

Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone inβ-thalassemia

(2009) Totsapol Jirasomprasert et al.   FREE RADICAL RESEARCH